Compare · JNJ vs SCPH
JNJ vs SCPH
Side-by-side comparison of Johnson & Johnson (JNJ) and scPharmaceuticals Inc. (SCPH): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both JNJ and SCPH operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- JNJ is the larger of the two at $560.33B, about 5238.7x SCPH ($107.0M).
- Over the past year, JNJ is up 49.0% and SCPH is up 33.6% - JNJ leads by 15.3 points.
- JNJ has hit the wire 8 times in the past 4 weeks while SCPH has been quiet.
- JNJ has more recent analyst coverage (25 ratings vs 6 for SCPH).
- Company
- Johnson & Johnson
- scPharmaceuticals Inc.
- Price
- $231.27-0.62%
- $5.68+0.00%
- Market cap
- $560.33B
- $107.0M
- 1M return
- +3.96%
- +1.88%
- 1Y return
- +48.99%
- +33.65%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2017
- News (4w)
- 8
- 0
- Recent ratings
- 25
- 6
Johnson & Johnson
Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; smoking cessation products under the NICORETTE brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides electrophysiology products to treat cardiovascular diseases and neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
scPharmaceuticals Inc.
scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. The company's lead product candidate is FUROSCIX that consists of proprietary buffered formulation of furosemide, which is delivered through the SmartDose drug delivery system for treatment of congestion in decompensated heart failure patients. Its product pipeline also includes scCeftriaxone, an antibiotic to treat infections caused by gram-positive and gram-negative organisms; and scCarbapenem program, an antibiotic for treating infections caused by gram-negative organisms. The company has a development agreement with West Pharmaceutical Services, Inc. to incorporate SmartDose drug delivery system with Furoscix. scPharmaceuticals Inc. was incorporated in 2013 and is headquartered in Burlington, Massachusetts.
Latest JNJ
- Johnson & Johnson to Acquire Firefly Bio, Inc. to Expand Oncology Pipeline with Novel Degrader Antibody Conjugate Platform
- Johnson & Johnson presents new data further reinforcing the role of nipocalimab in lowering the autoantibodies driving Sjögren's disease
- Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, breaking a decades-long treatment paradigm
- RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) demonstrates prolonged clinical benefit as a first-line treatment for atypical EGFR-mutated non-small cell lung cancer
- New TECVAYLI® (teclistamab-cqyv) data demonstrate superior progression-free and overall survival as early as first relapse in multiple myeloma
- FDA approves label expansion, cementing TREMFYA® as the only IL‑23 inhibitor proven to help stop further joint damage
- Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results
- SEC Form SD filed by Johnson & Johnson
- SEC Form 13F-HR filed by Johnson & Johnson
- CNS Drug Delivery Technologies Are Reshaping Alzheimer's and Biodefense Research
Latest SCPH
- SEC Form EFFECT filed by scPharmaceuticals Inc.
- SEC Form EFFECT filed by scPharmaceuticals Inc.
- SEC Form EFFECT filed by scPharmaceuticals Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by scPharmaceuticals Inc.
- SEC Form SCHEDULE 13G filed by scPharmaceuticals Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by scPharmaceuticals Inc.
- SEC Form 15-12G filed by scPharmaceuticals Inc.
- SEC Form SCHEDULE 13G filed by scPharmaceuticals Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by scPharmaceuticals Inc.
- Director Schaeffer Leonard D closing all direct ownership in the company (SEC Form 4)